Glenmark set to ink multi-billion dollar research deals

16930 Investors following Glenmark. Share this News with them.

0

Like this story, share it with millions of investors on M3

Glenmark set to ink multi-billion dollar research deals

Drug maker Glenmark is on the verge of signing a few multi-million dollar research deals, reports CNBC-TV18. The company has been in talks with several European players to out-license its anti-asthma drug.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Glenmark posts 64% consolidated revenue growth Glenmark Pharma Q4 net profit at Rs 62.56cr Glenmark Pharma Q4 seen up at Rs 47.8 cr ALSO READ See latest News about Glenmark See previous management interviews See what other Experts & Brokerages are saying about Glenmark Glenmark BSE | NSE 25/05/12 Are Mutual Funds betting on Glenmark?

Drug maker Glenmark is on the verge of signing a few multi-million dollar research deals, reports CNBC-TV18. The company has been in talks with several European players to out-license its anti-asthma drug.

Glenn Saldanha, MD and CEO, Glenmark, said his company's research pipeline looks very robust.  "The two that are open right now are 386 for Europe licencing and VR1 antagonist. In addition, our CV1 antagonist 10801 goes into clinical trials from next month. By the end of May we anticipate to start clinicals again in Europe on our CV1 antagonist. We are extremely excited about it. Molecules in Q2 that are going into clinical trials in Europe are GRC4039 which is PD4 and we have one more CB2 agonist for pain, which is GRC10693 that goes into clinicals," he said.

Glenmark has already signed deals for its molecules with US-based Forest Labs and German drug maker Merck.